Newsfeeds - Spark Newswire

1 minute read

FDA
News

Sorrento Announces FDA Authorization To Proceed With Phase 1 Study Of Intranasal STI-9199

Today, 4:56 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intranasal (IN) STI-9199

SRNE

30 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 4:56 AM

During Tuesday's trading, 505 companies set new 52-week lows.

ACRX

2 minute read

Sorrento Therapeutics Reports Purchase Of Majority Ownership In Zhengzhou Fortune Bioscience, No Terms Disclosed

By Benzinga Newsdesk

Today, 4:56 AM

COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant. COVISTIX has an enhanced sensitivity in detecting the Omicron

SRNE

1 minute read

Sorrento Therapeutics Granted U.S. Patent #11,242,391 ‘ Antigen binding proteins that bind PD-1’

By Charles Gross

Today, 4:56 AM

View patent here

SRNE

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 4:56 AM

AMPH

1 minute read

Sorrento’s COVID-19 Main Protease Inhibitor Neutralizes Omicron

By Vandana Singh

Today, 4:56 AM

Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558,

PFE

2 minute read

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558 ‘effectively inhibits Omicron virus entry and replication in cells.’

By Bill Haddad

Today, 4:56 AM

STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a

SRNE

4 minute read

Sorrento Therapeutics Reports Its Covishield ‘Potently’ Neutralizes Omicron, Omicron Variants Of SARS-CoV-2

By Benzinga Newsdesk

Today, 4:56 AM

COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) and further optimized and engineered by Sorrento

SRNE